Form 4: Penumbra Director Janet Leeds Receives RSU Grant

Penumbra Director Janet Leeds was granted 589 restricted stock units, which vest quarterly or upon the closing of a merger with Boston Scientific Corporation.

Summary

• Janet Leeds, a Director of Penumbra Inc., acquired 589 Restricted Stock Units (RSUs).
• The transaction date for the RSU acquisition was February 13, 2026.
• These RSUs will vest in four equal installments of 1/4 on March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026, contingent on Ms. Leeds' continued service as a director.
• An accelerated vesting clause states that any unvested RSUs will fully vest upon the 'Closing' of a merger agreement dated January 14, 2026, between Penumbra Inc., Boston Scientific Corporation, and Pinehurst Merger Sub, Inc., also subject to continued service.
• Following this transaction, Ms. Leeds beneficially owns 6,639 shares of common stock, a portion of which remains subject to vesting.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development. While a routine RSU grant, it signifies continued director alignment and hints at a significant strategic event (merger) that could unlock value, though the outcome remains uncertain.

Positives

• The grant of Restricted Stock Units to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The inclusion of an accelerated vesting clause upon a potential merger with Boston Scientific Corporation suggests strategic activity that could benefit shareholders.

Risks

• The vesting of the RSUs is contingent on Ms. Leeds' continued service as a director through the specified vesting dates.
• The accelerated vesting is dependent on the successful 'Closing' of the merger agreement with Boston Scientific Corporation, which may not occur.

Future Outlook

The future outlook for these RSUs involves a scheduled vesting over the next year, with the potential for accelerated vesting if the previously announced merger with Boston Scientific Corporation closes. Continued service as a director is a prerequisite for all vesting events.

Industry Context

StockSavvy.ai notes that routine RSU grants to directors are a standard practice in the medical technology industry, serving to align leadership incentives with long-term shareholder value. The explicit mention of a merger agreement with Boston Scientific Corporation, a major player in the medical device sector, indicates potential strategic consolidation or acquisition activity within the industry, which could have broader implications for competitive landscapes and market valuations.

Comparison to Industry Standards

• The grant of restricted stock units to a director is a common form of executive and director compensation across publicly traded companies, including those in the medical technology sector, aligning their interests with long-term company performance.
• The vesting schedule, with quarterly installments over a year, is typical for such equity awards, providing ongoing incentive for continued service.
• The inclusion of a change-of-control clause (accelerated vesting upon merger) is also a standard provision in many equity compensation plans, designed to protect executive and director interests in the event of an acquisition.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholder value through equity ownership. Potential for value creation if the merger with Boston Scientific Corporation successfully closes.
• Employees: No direct impact mentioned, but a merger could have broader implications for the workforce.
• Customers/Suppliers/Creditors: No direct impact mentioned in this filing.

Next Steps

• Continued service of Janet Leeds as a director through the specified vesting dates.
• Monitoring the progress and potential 'Closing' of the merger agreement with Boston Scientific Corporation.

Key Dates

Keywords

Penumbra Inc., PEN, Janet Leeds, Restricted Stock Units, RSU, Insider Transaction, Form 4, Director Compensation, Equity Grant, Vesting, Merger Agreement, Boston Scientific Corporation